Phase 2 Projects launched!
15th February 2018
We are delighted to announce today the two projects awarded Phase 2 funding for our New approaches to record and integrate cancer PROMs and PREMs SBRI funding competition.
My Clinical Outcomes Ltd and Px HealthCare Ltd have been awarded £100k each to embark on a six month phase for development and evaluation of a proof of concept/prototype. Further information about the projects can be found here.
All five Phase 1 projects achieved a tremendous amount in their three month feasibility phase and we look forward to bringing you news of how Docobo, Openbrolly and Sitekit are getting on with their projects.
In the meantime, congratulations to My Clinical Outcomes and Px HealthCare! Watch this space for news on their progress.
From our press release issued 15 February 2018
NEW TECH COULD EXTEND CANCER SURVIVAL RATE BY UP TO FIVE MONTHS WITH REAL-TIME SYMPTOM UPDATES
- Two innovative Scottish projects win £100k funding from Cancer Innovation Challenge
- Cancer patients to give clinicians real-time symptom updates to inform decisions
Cancer patients in Scotland could soon be able to share their symptoms with their medical team in real time using new technology after two new projects each received a £100,000 award to progress to the second phase of the prestigious Cancer Innovation Challenge.
Enabling cancer patients to share symptoms as they happen has been proven to improve treatment options and increase survival rates by up to five months*.
The two projects record so-called ‘Patient-Reported Outcome Measures’ (PROMs) and ‘Patient-Reported Experience Measures’ (PREMs) and integrate them with NHS technology systems. Allowing cancer patients to record symptoms such as pain, nausea or tiredness as they experience them gives doctors a more accurate understanding of their condition and how they are responding to treatment.
The tools will enhance cancer patients’ experiences during treatment, potentially improve their life expectancy and also deliver longer-term insights into the effectiveness of different treatments for clinicians.
Dr Catherine Calderwood, Scotland’s Chief Medical Officer, said: “Ensuring that the person receiving care is at the centre of medical decision making is crucial. Getting accurate information from patients about their symptoms at the time they are experiencing them is core to this. This is particularly pertinent for people with cancer. How they feel really matters.
“Patient-reported outcomes (PROs), using innovative tools such as these, will enable doctors to weigh-up risks and benefits of individuals’ treatments. It takes the pressure off the patient having to remember how they felt a week or two ago when they are coming in for their next appointment. Using such tools has the potential to enhance the quality of life for patients while they are going through treatment. Ultimately it is about improving services, treatments and outcomes for people with cancer.”
OWise is an app developed by Px HealthCare specifically for breast cancer patients. It will include a specific notification, which nudges patients to contact the Cancer Treatment Helpline in reaction to certain symptoms in a bid to address Scots’ reticence to ‘be a bother’. Crucially, the OWise tool, which provides clinicians with a real time view of patient reported outcomes, will be able to be integrated with TrakCare® – a patient management system widely used throughout NHS Scotland. Px is currently developing the tool in partnership with NHS Lothian and has had patient feedback via engagement with Maggie’s.
My Clinical Outcomes (MCO) is a web-platform used to collect and analyse variation in patient-reported outcomes. The platform has been tailored for patients in Scotland with any cancer type, and will be piloted with haematological cancer patients at NHS Ayrshire and Arran. Using MCO, patients answer regular assessments and track the impact of their condition on their life through a personal dashboard. Clinicians can immediately access this valuable new information about the effectiveness of treatment to inform ongoing clinical decisions. The solution has been designed to include guidance from Macmillan Cancer Support and is interoperable with Orion Healthcare, another well-established clinical portal in Scotland.
Both now have six months to further develop their prototypes and further demonstrate their benefits and roll-out potential.
Professor Andy Mount, Dean of Research, College of Science and Engineering, The University of Edinburgh and Chair, Strategic Management Board of Cancer Innovation Challenge, added: “The Board were impressed by the progress made by all five companies in Phase 1 of the PROMS PREMS call, especially when considering the tight budget and timescales. We congratulate those successful companies in the Phase 2 competition and look forward to the development of their technologies, to address the opportunity of harnessing data to drive innovation in cancer treatment in Scotland. We commiserate with those who were unsuccessful in this highly competitive call, and encourage them to engage through the Cancer Innovation Challenge’s project partners to explore progressing their technologies.”
The other projects involved phase one of the Cancer Innovation Challenge were:
‘Remote Patient Measures’ Docobo, Surrey
‘PROEMS – A flexible, future-proofed and integrated solution for PROM and PREM collection and use’ Openbrolly, Elgin
‘Digital platform for Teenage and Young Adult (TYA) cancer service in Scotland’ Sitekit Health, Isle of Skye
The Cancer Innovation Challenge aims to inspire novel data and tech innovations to help Scotland become a world leader in cancer care. It is funded by the Scottish Funding Council and delivered by three Scottish innovation centres – led by The Data Lab and supported by the Digital Health and Care Institute (DHI) and Stratified Medicine Scotland (SMS).
To find out more about the Cancer Innovation Challenge and its associated activities and funding opportunities, please visit www.cancerchallengescotland.com.
* Digital patient reported outcome measurement is flagged as a key cancer trend in 2018 by Forbes. According to a 2017 US study: Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment https://jamanetwork.com/journals/jama/fullarticle/2630810?alert=article
For further information, please contact:
Joanna Buggy, James Matheson or Ginny Fisher on 0131 226 2363 / datalab [at] grayling.com
Full Press Release available to download here
15 February 2018 DIGIT
15 February 2018 FutureScot
15 February 2018 The Scotsman Online
15 February 2018 Healthcare Tech News (HTN)
18 February 2018 Scotsman on Sunday (print)
21 February 2018 Building Better Healthcare (BBH)